We evaluated the progress until the third quarter and the fourth quarter outlook. As a result, net sales and operating income, which were revised upward after the second quarter, remain unchanged at ¥1,010.0 billion and ¥65.0 billion, respectively.
We will apply a fourth quarter FOREX assumption of ¥115 to the dollar and ¥135 to the euro. Under this assumption, although our outlook for net sales may exceed ¥1,010.0 billion, our announced forecast remains unchanged.
Both the Business Technologies Business and the performance materials field recorded solid performances, but a trend of softness has continued in the Healthcare Business. Therefore, our full-year forecast remains unchanged at ¥65.0 billion.
On the other hand, our net income forecast has been raised to ¥33.0 billion. We revised the initial forecast of ¥26.0 billion upward to ¥30.0 billion after the end of the fiscal first half, and now elevate it even more, resulting in a 51% year on year increase in profit.
In accordance with the Medium Term Business Plan, we are proceeding with sales of assets and a reduction of total assets. Also, a decrease in expected impairment risk and other risks is the main reason for our upward revision.
Regarding dividends, as we forecast at the beginning of the year, by combining a year-end dividend of ¥10 per share with the interim dividend, the annual dividend will be \20 per share. Last year, including the commemorative dividend of ¥2.5, the annual dividend was ¥17.5.
We will apply a fourth quarter FOREX assumption of ¥115 to the dollar and ¥135 to the euro. Under this assumption, although our outlook for net sales may exceed ¥1,010.0 billion, our announced forecast remains unchanged.
Both the Business Technologies Business and the performance materials field recorded solid performances, but a trend of softness has continued in the Healthcare Business. Therefore, our full-year forecast remains unchanged at ¥65.0 billion. On the other hand, our net income forecast has been raised to ¥33.0 billion. We revised the initial forecast of ¥26.0 billion upward to ¥30.0 billion after the end of the fiscal first half, and now elevate it even more, resulting in a 51% year on year increase in profit.
In accordance with the Medium Term Business Plan, we are proceeding with sales of assets and a reduction of total assets. Also, a decrease in expected impairment risk and other risks is the main reason for our upward revision.
Regarding dividends, as we forecast at the beginning of the year, by combining a year-end dividend of ¥10 per share with the interim dividend, the annual dividend will be \20 per share. Last year, including the commemorative dividend of ¥2.5, the annual dividend was ¥17.5.